Harmony Biosciences Holdings (HRMY) Raw Materials (2023 - 2024)
Harmony Biosciences Holdings (HRMY) reported Raw Materials of $944000.0 for Q4 2024, down 10.94% on a YoY basis from $1.1 million in Q1 2024, and down 8.62% sequentially from $1.0 million in Q3 2024.
Harmony Biosciences Holdings (HRMY) Raw Materials (2023 - 2024) Analysis & Trends
Harmony Biosciences Holdings (HRMY) has 2 years of Raw Materials data on file, last reported at $944000.0 in Q4 2024.
- For the quarter ending Q4 2024, Raw Materials fell 10.94% year-over-year to $944000.0; the trailing twelve-month figure through Dec 2024 stood at $944000.0 (down 10.94% YoY), and the FY2024 full-year result was $944000.0, down 10.94% from the prior year.
- Raw Materials retreated to $944000.0 in Q4 2024, from $1.0 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $1.1 million in Q2 2024 to a low of $944000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Harmony Biosciences Holdings | 2.07 Bn | 1.55 Bn | 170.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 944,000.00 |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.01 Mn |
| Dec 31, 2023 | 1.06 Mn |